Prognosis for Patients with Carcinoids
Most carcinoids grow slowly. The 5-year survival rate following surgical removal (resection) of a carcinoid tumor that has not metastasized is 70—90 percent. In approximately 45 percent of patients, metastases are present at the time of diagnosis. Patients with metastatic disease often live 1015 years. Carcinoid tumors that metastasize to the liver have a poor prognosis.
Newer Carcinoid Treatments
Advances in the treatment of malignant tumors come from laboratory research. This information is then translated into treatments appropriate for clinical trials. Such advancements can only be made with the voluntary participation of patients in clinical trials.
New and emerging treatments for carcinoid syndrome include therapy directed against cellular receptors, cellular enzymes, cellular antigens, and genes. Patients diagnosed with carcinoid syndrome can ask their physician about available research protocols and inquire into the possibility of participating in experimental treatment.